iBio (IBIO) Stock Price, News & Analysis

Company Overview

iBio, Inc. is a biotechnology company focused on discovering and developing next-generation antibody therapeutics. The company uses artificial intelligence, machine learning and computational biology to identify antibody candidates and optimize their properties for potential use in cancer, autoimmune, inflammatory and fibrotic diseases.

iBio’s technology platform is based in part on the antibody-discovery capabilities obtained through its acquisition of RubrYc Therapeutics. The platform is designed to support target selection, antibody generation and optimization, with an emphasis on identifying antibodies that bind specific disease-related epitopes. iBio is advancing its own discovery programs while also pursuing collaborations and licensing opportunities with pharmaceutical and biotechnology companies.

Historically, iBio operated as a biologics manufacturing and development company and was known for its FastPharming plant-based protein-production technology. The company has since shifted its primary focus toward artificial intelligence-enabled antibody discovery and therapeutic development. iBio is led by President and Chief Executive Officer Martin Brenner, Ph.D.

Key Stats

• Today's Range: $1.07 to $1.15
• 50-Day Range: $1.11 to $1.49
• 52-Week Range: $0.78 to $3.82
• Volume: 488,184 shs
• Average Volume: 1.12 million shs
• Market Capitalization: $72.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.29
• Consensus Rating: Buy

iBio Stock Analysis - MarketRank™

iBio scored higher than 58% of companies evaluated by MarketBeat, and ranked 406th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Buy

Consensus Rating

iBio has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 3 strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

iBio has a consensus price target of $5.29, representing about 374.5% upside from its current price of $1.11.

Amount of Analyst Coverage

iBio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for iBio are expected to decrease in the coming year, from ($0.39) to ($0.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of iBio is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of iBio is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

iBio has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.80% of the float of iBio has been sold short.

Short Interest Ratio / Days to Cover

iBio has a short interest ratio ("days to cover") of 9.99.

Change versus previous month

Short interest in iBio has recently decreased by 5.14%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iBio does not currently pay a dividend.

Dividend Growth

iBio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.26

News Sentiment

iBio has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for iBio this week, compared to 2 articles on an average week.

Search Interest

11 people have searched for IBIO on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, iBio insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.55% of the stock of iBio is held by insiders.

Percentage Held by Institutions

7.90% of the stock of iBio is held by institutions.

Company Calendar

• Last Earnings: 8/28/2026
• Today: 10/02/2026
• 3rd Annual Guggenheim Healthcare Innovation Conference: 11/10/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IBIO
• Previous Symbol: NYSEMKT:IBIO
• CIK: 1420720
• Web: ibioinc.com
• Phone: (302) 355-0650
• Fax: 302-356-1173
• Employees: 23
• Year Founded: N/A

Price Target and Rating

• Average Price Target for iBio: $5.29
• High Price Target: $7.00
• Low Price Target: $2.00
• Potential Upside/Downside: +369.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.04 million
• Net Margins: N/A
• Pretax Margin: -33,044.00%
• Return on Equity: -40.66%
• Return on Assets: -35.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.85
• Quick Ratio: 7.85

Sales & Book Value

• Annual Sales: $100 thousand
• Price / Sales: 723.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.54 per share
• Price / Book: 0.73

Miscellaneous

• Outstanding Shares: 64,310,000
• Free Float: 63,310,000
• Market Cap: $72.35 million
• Optionable: N/A
• Beta: 1.26